Speaker Profile

Director, Clinical Biomarkers and Diagnostics, Amgen

Biography
Dave Stanforth has over 20 years of experience in IVD / CDx development working in both diagnostic companies and pharma. He worked at Dako / Agilent where he held leadership positions in CDx product development, program management and business development. He led the development of the first companion and complementary diagnostics for PD-1 / PD-L1 checkpoint inhibitors in partnership with Merck and BMS. He joined Daiichi Sankyo in 2017 where he led the development of CDx assays for Daiichi’s ADC portfolio. Dave is currently heading up Diagnostic Strategy and Development for Amgen and is the global team lead for the development of CDx assays for Amgen’s G12C targeted therapy AMG 510.


×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by MAR. 28TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required